Tesamorelin (10mg)

Tesamorelin is a synthetic analogue of human GHRH (growth hormone-releasing hormone) comprising all 44 amino acids of native GHRH with an added trans-3-hexenoic acid moiety at the N-terminus. This modification enhances resistance to DPP-4 enzymatic degradation without altering receptor binding affinity, resulting in improved bioavailability compared to native GHRH. Tesamorelin is FDA-approved under the brand name Egrifta for the treatment of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, stimulating GH synthesis and secretion through the cAMP/PKA signaling cascade. Like sermorelin, it promotes physiological pulsatile GH release while preserving somatostatin-mediated feedback regulation. The resulting GH elevation stimulates hepatic IGF-1 production and downstream metabolic effects including lipolysis, particularly in visceral adipose depots. Clinical trials demonstrated significant reductions in visceral adipose tissue (VAT) — approximately 15-18% reduction over 26 weeks in HIV lipodystrophy patients. Importantly, tesamorelin reduced VAT without significantly affecting subcutaneous fat, suggesting preferential action on metabolically active visceral depots. Additional research has explored cognitive benefits, with Stanley et al. demonstrating improved executive function and verbal memory in older adults.

Tesamorelin is a synthetic analogue of human GHRH (growth hormone-releasing hormone) comprising all 44 amino acids of native GHRH with an added trans-3-hexenoic acid moiety at the N-terminus. This modification enhances resistance to DPP-4 enzymatic degradation without altering receptor binding affinity, resulting in improved bioavailability compared to native GHRH. Tesamorelin is FDA-approved under the brand name Egrifta for the treatment of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, stimulating GH synthesis and secretion through the cAMP/PKA signaling cascade. Like sermorelin, it promotes physiological pulsatile GH release while preserving somatostatin-mediated feedback regulation. The resulting GH elevation stimulates hepatic IGF-1 production and downstream metabolic effects including lipolysis, particularly in visceral adipose depots. Clinical trials demonstrated significant reductions in visceral adipose tissue (VAT) — approximately 15-18% reduction over 26 weeks in HIV lipodystrophy patients. Importantly, tesamorelin reduced VAT without significantly affecting subcutaneous fat, suggesting preferential action on metabolically active visceral depots. Additional research has explored cognitive benefits, with Stanley et al. demonstrating improved executive function and verbal memory in older adults.

The FDA-approved dose is 2 mg subcutaneously once daily. Clinical trials used 1-2 mg daily doses. Diagnostic GH stimulation protocols have also been studied.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.